Reduced levels of D-dimer and changes in gut microbiota composition after probiotic intervention in HIV-infected individuals on stable ART

Journal of Acquired Immune Deficiency Syndromes

Volumn 70, Issue 4, 2015, Pages 329-337

  Stiksrud, Birgitte ^a,b   Nowak, Piotr ^c   Nwosu, Felix C ^d   Kvale, Dag ^a,b   Thalme, Anders ^c   Sonnerborg, Anders ^c   Ueland, Per M ^e,f   Holm, Kristian ^g   Birkeland, Stein Erik ^h   Dahm, Anders E A ^b,i   Sandset, Per M ^b,j   Rudi, Knut ^d   Hov, Johannes R ^b,g,j   Dyrhol Riise, Anne M ^a,b   Trøseid, Marius ^a,b,g,j  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

^e UNIVERSITY OF BERGEN   (Norway)

^f HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h TINE SA   (Norway)

ⁱ AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^j OSLO UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

Chronic immune activation; D dimer; Gut microbiota; HIV; Inflammation; Probiotics

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; C REACTIVE PROTEIN; CD14 ANTIGEN; D DIMER; INTERLEUKIN 6; KYNURENINE; LIPOPOLYSACCHARIDE; PLACEBO; PROBIOTIC AGENT; TRYPTOPHAN; ANTIRETROVIRUS AGENT; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ADULT; ANTIVIRAL THERAPY; BACTERIAL TRANSLOCATION; BIFIDOBACTERIUM ANIMALIS; CATABOLISM; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE FLORA; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS RHAMNOSUS; MALE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; TH17 CELL; TRYPTOPHAN METABOLISM; AGED; BIOTA; BLOOD; HIV INFECTIONS; LYMPHOCYTE ACTIVATION; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; ANTIGENS, CD14; BACTERIAL TRANSLOCATION; BIOTA; DOUBLE-BLIND METHOD; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; GASTROINTESTINAL MICROBIOME; HIV INFECTIONS; HUMANS; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PLACEBOS; PROBIOTICS; TREATMENT OUTCOME;

EID: 84945897500     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000784     Document Type: Conference Paper

References (53)

1. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity. 2013;39:633-645.
2. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173:614-622.
3. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201:1788-1795.
4. Hunt PW, Sinclair E, Rodriguez B, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014;210:1228-1238.
5. Armah KA, McGinnis K, Baker J, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis. 2012;55:126-136.
6. Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;210:1248-1259.
7. Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One. 2012;7: e44454.
8. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203.
9. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203: 780-790.
10. Tien PC, Choi AI, Zolopa AR, et al. Inflammation and mortality in HIVinfected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr. 2010;55:316-322.
11. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365-1371.
12. Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis. 2014;58:588-595.
13. Cassol E, Malfeld S, Mahasha P, et al. Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. J Infect Dis. 2010;202: 723-733.
14. Brenchley JM, Paiardini M, Knox KS, et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood. 2008;112:2826-2835.
15. Cecchinato V, Trindade CJ, Laurence A, et al. Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol. 2008;1: 279-288.
16. Favre D, Mold J, Hunt PW, et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med. 2010;2:32ra36.
17. Gori A, Tincati C, Rizzardini G, et al. Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J Clin Microbiol. 2008;46: 757-758.
18. Vujkovic-Cvijin I, Dunham RM, Iwai S, et al. Dysbiosis of the gut microbiota is associated with hiv disease progression and tryptophan catabolism. Sci Transl Med. 2013;5:193ra191.
19. Dillon SM, Lee EJ, Kotter CV, et al. An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunol. 2014;7:983-994.
20. Dinh DM, Volpe GE, Duffalo C, et al. Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection. J Infect Dis. 2015;211:19-27.
21. Mutlu EA, Keshavarzian A, Losurdo J, et al. A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog. 2014;10:e1003829.
22. Perez-Santiago J, Gianella S, Massanella M, et al. Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection. AIDS. 2013;27:1921-1931.
23. Nowak P, Troseid M, Avershina E, et al. Gut microbiota diversity predicts immune status in HIV-1 infection. AIDS. 2015; [Epub ahead of print, September 9, 2015].
24. Gori A, Rizzardini G, Van't Land B, et al. Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trial. Mucosal Immunol. 2011;4:554-563.
25. Serrano-Villar S, Vásques-Catellanos J, Vallejo A, et al. Targeting gut dysbiosis with prebiotics and glutamine in HIV-infected subjects. Presented at: The annual Conference on Retroviruses and Opportunistic Infection; 2015; Seattle, WA. Abstract 266.
26. Klatt NR, Canary LA, Sun X, et al. Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. J Clin Invest. 2013;123:903-907.
27. Lewden C, Chene G, Morlat P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretro-viral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr. 2007;46:72-77.
28. van Hoffen E, Korthagen NM, de Kivit S, et al. Exposure of intestinal epithelial cells to UV-killed Lactobacillus GG but not Bifidobacterium breve enhances the effector immune response in vitro. Int Arch Allergy Immunol. 2010;152:159-168.
29. Troseid M, Nowak P, Nystrom J, et al. Elevated plasma levels of lipopolysaccharide and high mobility group box-1 protein are associated with high viral load in HIV-1 infection: reduction by 2-year antiretroviral therapy. AIDS. 2010;24:1733-1737.
30. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33:4-15.
31. Midttun O, Hustad S, Ueland PM. Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2009;23:1371-1379.
32. Naseribafrouei A, Hestad K, Avershina E, et al. Correlation between the human fecal microbiota and depression. Neurogastroenterol Motil. 2014; 26:1155-1162.
33. Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7:335-336.
34. McDonald D, Price MN, Goodrich J, et al. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J. 2012;6:610-618.
35. Pettersen FO, Torheim EA, Dahm AE, et al. An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses. J Virol. 2011;85:6557-6566.
36. Hemker HC, Al Dieri R, De Smedt E, et al. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost. 2006;96:553-561.
37. McHardy IH, Li X, Tong M, et al. HIV Infection is associated with compositional and functional shifts in the rectal mucosal microbiota. Microbiome. 2013;1:26.
38. Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood. 2009;113:2878-2887.
39. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation. 2004;109:2698-2704.
40. Funderburg NT, Mayne E, Sieg SF, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood. 2010; 115:161-167.
41. Ford ES, Greenwald JH, Richterman AG, et al. Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS. 2010;24:1509-1517.
42. Betene ADC, De Wit S, Neuhaus J, et al. Interleukin-6, high sensitivity C-reactive protein, and the development of type 2 diabetes among HIVpositive patients taking antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;67:538-546.
43. Ciorba MA, Riehl TE, Rao MS, et al. Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner. Gut. 2012;61:829-838.
44. Khailova L, Petrie B, Baird CH, et al. Lactobacillus rhamnosus GG and Bifidobacterium longum attenuate lung injury and inflammatory response in experimental sepsis. PLoS One. 2014;9:e97861.
45. Gonzalez-Hernandez LA, Jave-Suarez LF, Fafutis-Morris M, et al. Synbiotic therapy decreases microbial translocation and inflammation and improves immunological status in HIV-infected patients: a doubleblind randomized controlled pilot trial. Nutr J. 2012;11:90.
46. Villar-Garcia J, Hernandez JJ, Guerri-Fernandez R, et al. Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: a double-blind, randomized, placebo-controlled trial. J Acquir Immune Defic Syndr. 2014;68:256-263.
47. Sandler NG, Zhang X, Bosch RJ, et al. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis. 2014;210:1549-1554.
48. Tenorio AR, Chan ES, Bosch RJ, et al. Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIVpositive immune non-responders to antiretroviral therapy-ACTG A5286. J Infect Dis. 2014;211:780-790.
49. Wang Z, Xiao G, Yao Y, et al. The role of bifidobacteria in gut barrier function after thermal injury in rats. J Trauma. 2006;61:650-657.
50. Dewulf EM, Cani PD, Claus SP, et al. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulintype fructans in obese women. Gut. 2013;62:1112-1121.
51. Chang PV, Hao L, Offermanns S, et al. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci U S A. 2014;111:2247-2252.
52. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59-65.
53. Davis LM, Martinez I, Walter J, et al. Barcoded pyrosequencing reveals that consumption of galactooligosaccharides results in a highly specific bifidogenic response in humans. PLoS One. 2011;6:e25200.